Published in J Clin Oncol on March 01, 1994
Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis | NCT00646555
Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol (1995) 4.37
Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest (1997) 3.39
Intra-tumoural microvessel density in human solid tumours. Br J Cancer (2002) 1.60
Angiogenesis and breast cancer. J Clin Oncol (1994) 1.56
The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer (2012) 1.44
E-selectin is present in proliferating endothelial cells in human hemangiomas. Am J Pathol (1996) 1.35
Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer (1995) 1.26
Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer (1998) 1.25
Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br J Cancer (1996) 1.24
Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer (1998) 1.23
Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012. Geburtshilfe Frauenheilkd (2013) 1.14
Examining the technique of angiogenesis assessment in invasive breast cancer. Br J Cancer (1997) 1.12
Potential angiogenic role of platelet-activating factor in human breast cancer. Am J Pathol (1998) 1.11
The combination of angiogenesis and blood vessel invasion as a prognostic indicator in primary breast cancer. Br J Cancer (2003) 1.09
Endothelin B receptor, a new target in cancer immune therapy. Clin Cancer Res (2009) 1.05
Prognostic significance of lymphovascular invasion in radical cystectomy on patients with bladder cancer: a systematic review and meta-analysis. PLoS One (2014) 1.00
The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer (2002) 0.99
Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br J Cancer (2005) 0.98
Microvessel quantitation in invasive breast cancer by staining for factor VIII-related antigen. Br J Cancer (1995) 0.98
Fully automated microvessel counting and hot spot selection by image processing of whole tumour sections in invasive breast cancer. J Clin Pathol (1999) 0.97
Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer. Br J Cancer (2005) 0.97
Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer (1999) 0.96
Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer? Br J Cancer (1999) 0.95
Vascular grading of angiogenesis: prognostic significance in breast cancer. Br J Cancer (2000) 0.95
The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma. Br J Cancer (1999) 0.94
Differential expression of hypoxia and (lymph)angiogenesis-related genes at different metastatic sites in breast cancer. Clin Exp Metastasis (2007) 0.94
Clinicopathologic study associated with long-term survival in Japanese patients with node-negative breast cancer. Br J Cancer (2000) 0.90
Tissue inhibitor of metalloproteinase-3 (TIMP3) promotes endothelial apoptosis via a caspase-independent mechanism. Apoptosis (2015) 0.87
The relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancer. BMC Clin Pathol (2013) 0.87
Inhibition of tumor angiogenesis and growth by nanoparticle-mediated p53 gene therapy in mice. Cancer Gene Ther (2012) 0.87
Angiogenesis in oral squamous cell carcinoma. Acta Otorhinolaryngol Ital (2005) 0.86
Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour. Br J Cancer (2000) 0.86
Continuous representation of tumor microvessel density and detection of angiogenic hotspots in histological whole-slide images. Oncotarget (2015) 0.85
Tumor angiogenesis. The future is now. Ann Surg (1995) 0.84
Correlation between Blood Flow Signal of Color Flow Imaging and Nottingham Prognostic Index in Patients with Breast Carcinoma. Breast Care (Basel) (2012) 0.84
Prognostic significance of microvessel density and other variables in Japanese and British patients with primary invasive breast cancer. Br J Cancer (2007) 0.83
Vasculature in Nontumorous Hypophyses, Pituitary Adenomas, and Carcinomas: A Quantitative Morphologic Study. Endocr Pathol (1995) 0.83
Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast. J Clin Pathol (2002) 0.83
Downregulated MTAP expression in myxofibrosarcoma: A characterization of inactivating mechanisms, tumor suppressive function, and therapeutic relevance. Oncotarget (2014) 0.83
Independent prognostic importance of microvessel density in endometrial carcinoma. Br J Cancer (1998) 0.82
Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. Invest New Drugs (1997) 0.82
Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer. BMC Cancer (2014) 0.82
Euclidean and fractal geometry of microvascular networks in normal and neoplastic pituitary tissue. Neurosurg Rev (2008) 0.81
Microvessel density and status of p53 protein as potential prognostic factors for adjuvant anthracycline chemotherapy in retrospective analysis of early breast cancer patients group. Pathol Oncol Res (2012) 0.81
Development of a new metastatic human breast carcinoma xenograft line. Br J Cancer (1998) 0.80
Overexpression of mutant p53 and c-erbB-2 proteins and breast tumour take in mice. Br J Cancer (1995) 0.80
Is a histological section representative of whole tumour vascularity in breast cancer? Br J Cancer (1997) 0.79
Exploring molecular links between lymph node invasion and cancer prognosis in human breast cancer. BMC Syst Biol (2011) 0.79
Tumour microvessel density as predictor of chemotherapy response in breast cancer patients. Br J Cancer (2002) 0.79
Defective p53 antiangiogenic signaling in glioblastoma. Neuro Oncol (2010) 0.79
Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants. Br J Cancer (1998) 0.78
Microvessel density, p53 overexpression, and apoptosis in invasive breast carcinoma. Mol Pathol (1997) 0.78
Angiogenesis in Breast Cancer and its Correlation with Estrogen, Progesterone Receptors and other Prognostic Factors. J Clin Diagn Res (2015) 0.77
C-terminal domain of p42 Ebp1 is essential for down regulation of p85 subunit of PI3K, inhibiting tumor growth. Sci Rep (2016) 0.77
The preclinical evaluation of angiogenesis inhibitors. Invest New Drugs (1997) 0.76
Application of Canonical Correlation Analysis for Detecting Risk Factors Leading to Recurrence of Breast Cancer. Iran Red Crescent Med J (2016) 0.75
The future in advanced prostate cancer: take your partners or is the last dance for me? Rev Urol (2004) 0.75
A natural food sweetener with anti-pancreatic cancer properties. Oncogenesis (2016) 0.75
Bevacizumab for the treatment of recurrent ovarian cancer: a retrospective cohort study. Eur J Gynaecol Oncol (2013) 0.75
Reproducibility of microvessel counts in breast cancer specimens. Br J Cancer (1999) 0.75
Tumour location within the breast: Does tumour site have prognostic ability? Ecancermedicalscience (2015) 0.75
Angiogenesis in Endocrine Neoplasms. Endocr Pathol (1997) 0.75
Behaviour of metastasis in relation to vascular index in patients with node-positive breast cancer treated with adjuvant tamoxifen. Clin Exp Metastasis (2000) 0.75
Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy. Lancet (1999) 12.51
Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst (1992) 8.69
Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med (1981) 7.53
Regulation of longevity and stress resistance by Sch9 in yeast. Science (2001) 5.93
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst (1999) 4.04
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer (1996) 3.07
Dietary factors and risk of breast cancer: combined analysis of 12 case-control studies. J Natl Cancer Inst (1990) 3.02
Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial. Eur J Cancer (1990) 3.01
Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol (2001) 2.89
Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer (2002) 2.82
Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst (1995) 2.52
The adolescent growth spurt of boys and girls of the Harpenden growth study. Ann Hum Biol (1976) 2.19
Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst (1995) 2.10
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol (2006) 2.10
Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci (1986) 2.07
The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst (1994) 2.06
Comparison of Halsted mastectomy with quadrantectomy, axillary dissection, and radiotherapy in early breast cancer: long-term results. Eur J Cancer Clin Oncol (1986) 2.05
Pseudoangiomatous hyperplasia of mammary stroma. Some observations regarding its clinicopathologic spectrum. Cancer (1989) 2.02
Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer (1987) 2.01
Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg (1999) 2.00
Diagnostic relevance of clonal cytogenetic aberrations in malignant soft-tissue tumors. N Engl J Med (1991) 1.99
Confidence interval estimation for DNA and mRNA concentration by real-time PCR: A new environment for an old theorem. Int J Biol Markers (2004) 1.90
AKT1(E17K) in human solid tumours. Oncogene (2008) 1.87
Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst (1997) 1.87
PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol (1992) 1.86
Cutaneous granulomatous reaction to injectable hyaluronic acid gel. Br J Dermatol (2006) 1.80
Linear accelerator radiosurgery of cerebral arteriovenous malformations: an update. Neurosurgery (1994) 1.78
Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol (1998) 1.77
The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial. Eur J Cancer (1999) 1.73
Endothelial-like cells derived from human CD14 positive monocytes. Differentiation (2000) 1.73
Ten year results of a randomised trial comparing two conservative treatment strategies for small size breast cancer. Eur J Cancer (1998) 1.68
Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res (1994) 1.63
Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol (2011) 1.57
Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Cancer J Sci Am (2006) 1.54
Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol (1994) 1.52
Post-irradiation malignant mesothelioma. Cancer (1996) 1.52
Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum (1996) 1.51
Schwann cell seeded guidance tubes restore erectile function after ablation of cavernous nerves in rats. J Urol (2004) 1.51
Solitary fibrous tumor involving the renal capsule. Am J Surg Pathol (1996) 1.50
Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol (2001) 1.47
Anaplastic large cell lymphomas: a study of 75 pediatric patients. Pediatr Dev Pathol (2007) 1.46
The virtual case: a new method to completely digitize cytological and histological slides. Virchows Arch (2001) 1.46
p53 Protein expression in nevi and melanomas. Arch Dermatol (1993) 1.44
Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int J Cancer (1993) 1.44
Nucleolar organizer regions in mucinous tumours of the ovary. Histopathology (1990) 1.40
Quality control for biomarker determination in oncology: the experience of the Italian Network for Quality Assessment of Tumor Biomarkers (INQAT). Int J Biol Markers (2002) 1.40
Alopecia universalis in liver transplant patients treated with cyclosporin. Br J Dermatol (1995) 1.40
p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst (1993) 1.39
Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res (1995) 1.39
Dosimetric considerations on multiple arc stereotaxic radiotherapy. Radiother Oncol (1988) 1.39
Corpora cavernosa ultrastructure in vascular erectile dysfunction. J Urol (1990) 1.39
Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst (1993) 1.37
Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer (1997) 1.34
Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. Radiology (1996) 1.33
Total versus subtotal gastrectomy: surgical morbidity and mortality rates in a multicenter Italian randomized trial. The Italian Gastrointestinal Tumor Study Group. Ann Surg (1997) 1.32
Tumor angiogenesis, the p53 antigen, and cervical metastasis in squamous carcinoma of the tongue. Otolaryngol Head Neck Surg (1994) 1.31
Conservative treatment of early breast cancer. Long-term results of 1232 cases treated with quadrantectomy, axillary dissection, and radiotherapy. Ann Surg (1990) 1.28
Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol (1995) 1.27
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer (2004) 1.26
Feed forward neural networks for the analysis of censored survival data: a partial logistic regression approach. Stat Med (1998) 1.24
Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol (1995) 1.22
HDL-cholesterol and breast cancer: a joint study in northern Italy and southern France. Int J Epidemiol (1993) 1.22
Quantitative growth fraction evaluation with MIB1 and Ki67 antibodies in breast carcinomas. Am J Clin Pathol (1994) 1.22
Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol (1988) 1.21
Carcinosarcoma of the colon. Report of a unique case with light and immunohistochemical studies. Cancer (1986) 1.21
Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions. Br J Haematol (1996) 1.20
Tumour vascularity and proliferation: clear evidence of a close relationship. J Pathol (1999) 1.19
Rapp-Hodgkin syndrome and AEC syndrome: are they the same entity? Br J Dermatol (1994) 1.18
Immunohistochemistry of small round-cell tumors. Semin Diagn Pathol (2000) 1.17
Tumour suppressor gene products, proliferation, and differentiation markers in lung neuroendocrine neoplasms. J Pathol (1992) 1.16
Clinical management of a case of recurrent apocrine gland carcinoma of the scalp: efficacy of a chemotherapy schedule with methotrexate and bleomycin. Tumori (2001) 1.16
Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol (1994) 1.15
Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol (2001) 1.15
Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol (1996) 1.15
Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res (1996) 1.14
Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol (1992) 1.14